Non-COVID-19 sepsis (Sepsis) has always been one of the common diseases in critically ill patients. The main treatment strategy is to kill pathogens and mitigate hyperinflammation. One study demonstrated that the supplementation with 576,000 IU cholecalciferol (vitamin D3) as a single dose in critically ill adults in the medical intensive care units (MICUs) can improve clinical outcomes, including acute physiology and chronic health evaluation II score (APACHE II), sequential organ failure assessment score (SOFA), and C-reactive protein (CRP).
It is a three-year, multi-center, prospective, parallel, double-blind, randomized controlled clinical trial for 240 eligible subjects, with administrations of vitamin D3 576,000 IU or placebo every 24 hours for 3 days (72 hours) within 96 hours after intensive care unit (ICU) admission.

Start Date01 Jul 2024

Sponsor / Collaborator

Chi Mei Medical Center

[+1]

NCT06351566 / RecruitingNot ApplicableIIT

Effects of Vitamin D3 and Prebiotics Supplementation on Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Randomized Double-Blind Controlled Trial

The goal of this randomized, double-blind, placebo-controlled, 6-month supplementation study in individuals with type 2 diabetes is to investigate whether taking daily dietary supplements of vitamin D3 (1600 IU) or prebiotics (inulin, 10 gram) has beneficial effects on cardiovascular disease risk factors.

Start Date25 Apr 2024

Sponsor / Collaborator

Huazhong University of Science & Technology

IRCT20230831059311N1 / RecruitingPhase 3IIT

Investigating the effect of Sarcomeal oral supplementation and vitamin D3 on muscle parameters and metabolic factors in patients with diabetic sarcopenia: a randomized open-label clinical trial with parallel groups

Start Date08 Apr 2024

Sponsor / Collaborator

Tehran University of Medical Sciences

[+1]

100 Clinical Results associated with Colecalciferol

100 Translational Medicine associated with Colecalciferol

100 Patents (Medical) associated with Colecalciferol

18,503

Literatures (Medical) associated with Colecalciferol

01 Dec 2024·Molecular biology reports

Changes in miRNA expression in the lungs of pigs supplemented with different levels and forms of vitamin D

Article

Author: Wierzbicka, Alicja ; Świątkiewicz, Małgorzata ; Pawlina-Tyszko, Klaudia ; Szmatoła, Tomasz ; Oczkowicz, Maria

Abstract:

Background:

Vitamin D is an immunomodulator, and its effects have been linked to many diseases, including the pathogenesis of cancer. However, the effect of vitamin D supplementation on the regulation of gene expression of the lungs is not fully understood. This study aims to determine the effect of the increased dose of cholecalciferol and a combination of cholecalciferol + calcidiol, as well as the replacement of cholecalciferol with calcidiol, on the miRNA profile of healthy swine lungs.

Methods and results:

The swine were long-term (88 days) supplemented with a standard dose (2000IU/kg) of cholecalciferol and calcidiol, the increased dose (3000 IU/kg) of cholecalciferol, and the cholecalciferol + calcidiol combination: grower: 3000 IU/Kg of vitamin D (67% of cholecalciferol and 33% of calcidiol), finisher 2500 IU/Kg of vitamin D (60% of cholecalciferol and 40% of calcidiol). Swine lung tissue was used for Next Generation Sequencing (NGS) of miRNA. Long-term supplementation with the cholecalciferol + calcidiol combination caused significant changes in the miRNA profile. They embraced altered levels of the expression of miR-150, miR-193, miR-145, miR-574, miR-340, miR-381, miR-148 and miR-96 (q-value < 0.05). In contrast, raising the dose of cholecalciferol only changed the expression of miR-215, and the total replacement of cholecalciferol with calcidiol did not significantly affect the miRNAome profile.

Conclusions:

The functional analysis of differentially expressed miRNAs suggests that the use of the increased dose of the cholecalciferol + calcidiol combination may affect tumorigenesis processes through, inter alia, modulation of gene regulation of the TGF- β pathway and pathways related to metabolism and synthesis of glycan.

01 Apr 2024·The Journal of steroid biochemistry and molecular biology

In silico characterization of the novel SDR42E1 as a potential vitamin D modulator

Article

Author: Hendi, Nagham Nafiz ; Nemer, Georges

The short-chain dehydrogenase/reductase (SDR) superfamily encompasses enzymes that play essential roles in the metabolism of steroid hormones and lipids. Despite an enigmatic function, recent genetic studies have linked the novel SDR 42 extended-1 (SDR42E1) gene to 25-hydroxyvitamin D levels. This study investigated the potential SDR42E1 functions and interactions with vitamin D using bioinformatics and molecular docking studies. Phylogenetic analysis unveiled that the nucleotide sequences of human SDR42E1 exhibit high evolutionary conservation across nematodes and fruit flies. Molecular docking analysis identified strong binding affinities between SDR42E1 and its orthologs with vitamin D₃ and essential precursors, 8-dehydrocholesterol, followed by 7-dehydrocholesterol and 25-hydroxyvitamin D. The hydrophobic interactions observed between the protein residues and vitamin D compounds supported the predicted transmembrane localization of SDR42E1. Our investigation provides valuable insights into the potential role of SDR42E1 in skin vitamin D biosynthesis throughout species. This provides the foundation for future research and development of targeted therapies for vitamin D deficiency and related health conditions.

01 Apr 2024·Journal of exercise science and fitness

The effect of aquatic training and vitamin D3 supplementation on bone metabolism in postmenopausal obese women

Article

Author: Tamaddon, Gholamhossein ; Koushkie Jahromi, Maryam ; Zaravar, Leila ; Zaravar, Foroozandeh

Purpose:

Despite prevalence of studies indicating the positive effect of land-based exercise on bone metabolism, there are limited findings regarding the effect of aquatic exercise. The present study aimed to evaluate the effects of aquatic training and vitamin D3 supplementation on femur bone mineral density (BMD), serum 25(OH)D, and parathyroid hormone (PTH) in postmenopausal obese women with vitamin D insufficiency.

Methods:

40 postmenopausal obese women were randomly divided into four groups of aquatic training + vitamin D3 intake group; (ATD), aquatic training with placebo intake group (AT), vitamin D3 intake group (D), and control group with placebo intake (CON). AT groups performed aerobic aquatic exercises for 8 weeks. Vitamin D3 supplementation groups consumed oral dose of 4000 IU/d for 8 weeks.

Results:

The femur BMD was significantly higher in the ATD than the AT and D and CON groups; in AT it was higher than the D and CON groups. Serum 25(OH)D level in the ATD was more than AT and CON, and in the D was more than the CON and AT. PTH in the ATD group was lower compared to AT, D, and CON groups. PTH was lower in the AT and D compared to the CON.

Conclusion:

In postmenopausal obese women with vitamin D insufficiency or deficiency, combining vitamin D supplementation and aquatic training was the most effective method for improving bone metabolism; Vitamin D supplementation (alone) was not sufficient to affect some of bone metabolism indices; Aquatic training could not improve serum vitamin D. By priority, ATD, AT, and D indicated better bone related metabolism indices.

News (Medical) associated with Colecalciferol

11 Apr 2024

·www.prnewswire.com

Revival Point® Launches Total Male Vitality® Featuring RipFACTOR® Muscle Accelerator

New Product Will Help Men Get Their 'Mojo' Back Through Increased Strength, More Endurance and Improved Physique* MORRISTOWN, N.J., April 11, 2024 /PRNewswire/ -- PLT Health Solutions, Inc. announced that Revival Point, a health and wellness company that creates innovative health supplements and brands combined with strong partnerships and unique stories, has launched a new men's health product called Total Male Vitality®. The new product features PLT's RipFACTOR® Muscle Accelerator, an award-winning ingredient that has been shown in multiple gold standard clinical studies to enhance muscle strength and endurance and contribute to muscle growth, as well as increased testosterone levels. Total Male Vitality represents Revival Point's first entry into the men's health category. Continue Reading According to Steve Fink, Vice President of Marketing for PLT Health Solutions, Revival Point' is an exciting addition to the men's health marketplace. "One of the great things about RipFACTOR is that clinical trials point to statistically significant improvements starting at 14 days." "The combination of benefits and the clinical support behind RipFACTOR is like nothing else on the market today, in the sense that it helps you build more muscle in half the time - naturally.* I personally think that's something most companies wish they could advertise with their products, but don't have the studies to support it," Kendal LaFleur said. Total Male Vitality also features ZinMax™ zinc picolinate for hormone and immune support, as well as vitamin D3 and folate to support general health. The product will be available on the Revival Point website () as well as at Amazon, eBay and Walmart. According to Kendal LaFleur / Product Development Manager for Revival Point, the addition of RipFACTOR to this formulation will help the company offer consumers a premium men's health product that delivers clinically demonstrated results – with a great origin story. "The combination of benefits and the clinical support behind RipFACTOR is like nothing else on the market today, in the sense that it helps you build more muscle in half the time – naturally.* I personally think that's something most companies wish they could advertise with their products, but don't have the studies to support it," Kendal LaFleur said. "With Total Male Vitality, we're excited to offer a solution that stands out from the crowd. Our formulation features science-backed ingredients, including the latest clinical research on RipFACTOR," Kendal LaFleur added. Groundbreaking sports/active clinical studies RipFACTOR Muscle Accelerator is composed of two standardized botanical extracts with a rich Ayurvedic history: East Indian Globe Thistle (Spaeranthus indicus) and Mango Tree Bark (Mangifera indica) specifically standardized in a multi-patented formulation. In two clinical trials, participants consuming RipFACTOR showed as much as a 4x increase in muscle size and as much as a 2x improvement in muscle endurance relative to participants taking a placebo – with statistically significant results shown starting at 14 days. They also experienced up to a 5.6x improvement in upper body strength and up to a 5x improvement in lower body strength compared to subjects on placebo. Statistically significant improvements in lean body mass, percent body fat and total body fat were also observed. Compelling improvements in hormone balance were shown for both studies as well.* According to Steve Fink, Vice President of Marketing for PLT Health Solutions, Revival Point' is an exciting addition to the men's health marketplace. "One of the great things about RipFACTOR is that clinical trials point to statistically significant improvements starting at 14 days. Fast results like these are known to encourage continued use of a product and commitment to an exercise regimen. PLT Health Solutions is excited to work with Revival Point on developing this product and we look forward to bringing the benefits of RipFACTOR to many, many people alongside them," he said For more information on Total Male Vitality, visit: For more information on RipFACTOR visit: *These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. About Revival Point Since our inception in 2015, Revival Point's mission has been to enhance the well-being and vitality of men and women nationwide. Proudly all-natural, our vegetarian formulas are free from gluten, soy, allergens, and dairy, with every ingredient meticulously sourced and tested in the USA. In collaboration with leading doctors and researchers, we continuously integrate the latest findings in digestive health to ensure our products profoundly improve our customers' lives. About PLT Health Solutions Headquartered in Morristown, NJ, USA, PLT Health Solutions is a trusted discoverer, developer, and marketer of high-quality, scientifically supported ingredients that enhance health and functionality. As a leading ingredients innovator, PLT's global network of strategic partnerships provides unique access to impactful solutions. PLT Health Solutions is a purpose-driven company passionate about helping people live healthier, happier lives. By delivering an unsurpassed mix of expertise, resources, and service, PLT is committed to helping both its strategic partners and valued customers grow. Media Contact: Mark Falconer Sciencewerks 407-412-9705 E-mail: [email protected] PLT Company Contact: Steve Fink PLT Health Solutions, Inc. E-mail: [email protected] Revival Point Contact: Kendal LaFleur E-mail: [email protected] SOURCE PLT Health Solutions

Clinical Result

02 Apr 2024

·www.globenewswire.com

Pressure BioSciences’ Uncle Bud’s Subsidiary Reports Significant Demand for New UltraShear CBD Body Revive Spray – First Product in New “Premium Collection”

PBIO Receives Critical Processor License for Industrial Hemp in MA.New License and Relocation to Enhanced Manufacturing Facility Allows Company to Supplement Production with West Coast Partner to Manage Anticipated Onset of Purchase Order Increases. CANTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for the health & wellness, food & beverage, nutraceutical, cosmeceutical, and other industries, today announced that its wholly-owned Uncle Bud’s Health & Wellness consumer packaged goods subsidiary (“Uncle Bud’s”) has experienced significant sales activity in its revolutionary nanoemulsified CBD product offered in the initial launch of its highly touted “Premium Collection” of UltraShear™ processed nanoemulsion products. Click here for more info on Uncle Bud's Premium Collection. In an exciting move for natural wellness enthusiasts, Uncle Bud’s recently launched its UltraShear-processed “Premium Collection” of state-of-the-art nanoemulsified products, representing the pinnacle of innovation, quality, and commitment to clean and all-natural wellness solutions. The Premium Collection was an immediate success, highlighted by the unprecedented response to its initial product in the Collection - the CBD Body Revive Spray with 1200mg of Nano-CBD. PBIO’s multi-patented Ultra Shear Technology™ (UltraShear™ or UST™) platform allows oil-soluble active molecules (e.g., vitamin D3, retinol, CBD) to be prepared into high quality nanoemulsions that ensure rapid absorption and unparalleled bioavailability of the oil-based active ingredients into the water-based biochemistry of humans, animals, and plants. A recently published scientific study in a peer-reviewed journal by world-renowned researchers confirmed PBIO’s UltraShear nanoemulsion platform vastly outperformed other delivery systems with unmatched speed, efficiency, and bioavailability. UltraShear Bioavailability Study 2023. “Uncle Bud’s newly launched Nano-CBD Body Revive Spray, an innovative, all plant-based, organic, highly bioavailable flagship product processed using PBIO’s UltraShear platform, captured an impressive 30% conversion of Uncle Bud’s total CBD Revive Spray product revenue in March alone,” commented John Hollister, PBIO’s Director of Sales and Marketing. “The surge in demand for this revolutionary new product prompted an urgent restocking of this initial product in Uncle Bud’s Premium Collection, in order to meet the enthusiastic consumer response to date!” In a separate, critically important accomplishment, PBIO announced it had received its Massachusetts processing license for industrial hemp (No. 25240244P). The license was granted by the MA Department of Agricultural Resources (“MDAR”), the hemp processing licensing entity under federal and state law in the Commonwealth of MA. This achievement enables PBIO to develop, manufacture, market, and sell UST-processed products into the rapidly expanding CBD marketplace. Ken Micciche, PBIO’s Director of Business Development, added: “With our relocation into a larger and significantly enhanced manufacturing facility, with our new MDAR processor license, and with an accelerated focus on the generation of major revenue from sales of our unique nanoemulsified products, we are now prepared for the expected onset of orders for existing (e.g., CBD, Astaxanthin) and new (e.g., Acai, Retinol) UltraShear-processed nanoemulsified products.” About Uncle Bud’s Health and WellnessLaunched in 2018 with a trailblazing hemp-based Pain Relief product, Uncle Bud’s has rapidly captured an innovative leadership role in the Hemp Seed Oil, Cannabidiol (CBD), and the broader Health & Wellness industry. The Uncle Bud’s brand is revered for its unwavering commitment to domestic manufacturing excellence, setting benchmarks for its organic, preservative-free, non-GMO standards and its ethical cruelty-free practices. Uncle Bud’s is dedicated to the highest-quality formulations and to continuous improvement, guided by the latest scientific research and development innovations – including the revolutionary performance breakthroughs delivered by PBIO’s patented UltraShear™ processing platform. Uncle Bud’s diverse product portfolio addresses an ever-broadening spectrum of consumer needs, encompassing pain relief, sophisticated skincare solutions, personal wellness and athletic recovery products, and specialized pet care items. Learn More: www.unclebudshemp.com * Follow Us On Social Media: @UncleBuds_Hemp. About Pressure BioSciences, Inc.Pressure BioSciences, Inc. (OTCQB: PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our patented, scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform allows for the creation of stable nanoemulsions of otherwise immiscible oil-based active components in water. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our patented original enabling platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. Our patented BaroFold™ technology platform positions us to provide valuable contract services and GMP manufacturing equipment to the bio-pharmaceuticals industry. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers. Forward Looking StatementsThis press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. For more information about PBIO, Uncle Bud’s, and this press release, please click on the following website links:http://www.pressurebiosciences.com www.unclebudshemp.com Please visit us on Facebook, LinkedIn, and Twitter. CBD Body Revive SprayAll Natural, Fast Acting, Plant Based, Preservative Free, Best-in-Class,UltraShear-processed Nano CBD…the first in a series of groundbreaking premium nanoemulsified products designed to meet the needs of consumers looking for the highest quality and performance in natural and effective wellness solutions.Click here for more info on Uncle Bud's Premium Collection. Press Contacts: Richard T. Schumacher, President & CEOJohn B. Hollister, Director of Sales and MarketingKenneth F. Micciche, Director of Business Development (508) 230-1828 (T)(805) 908-5719 (T)(508) 230-1828 (T) A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6a5bec8b-25e8-44cb-83de-1368fd142375

License out/in

19 Mar 2024

·www.biospace.com

IRLAB’s Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson’s Disease Psychosis

GOTHENBURG, SE / ACCESSWIRE / March 19, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 19 March 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that a scientific paper reporting the effects of IRLAB's candidate drug mesdopetam in a preclinical model of Parkinson's disease psychosis (PD-P) has been published in the journal Neurotherapeutics. The paper reports a series of preclinical studies performed by the group for Integrative Neurophysiology, Lund University, Sweden, in collaboration with scientists at IRLAB. The studies are based on characterization of the neurophysiological brain state in an advanced preclinical model of PD-P. The effects of Mesdopetam, along with two compounds, clozapine and pimavanserin, which are clinically used to alleviate PD-P, and an experimental D3 antagonist, were investigated in this model. The studies concluded that mesdopetam displays key features associated with antipsychotic efficacy in this PD-P model and should be further explored as a potential novel treatment option for psychosis in Parkinson's disease. "The brain state characterization presented in the paper is an impressive new technique which enables a new level of understanding of the brain mechanisms underlying PD-P and provides a great tool for evaluation of potential new therapies. These new results strongly support that mesdopetam has potential as a novel therapeutic in PD-P, also in light of the excellent safety and tolerability pro in clinical studies with mesdopetam," says Nicholas Waters, EVP & Head of R&D at IRLAB. For more information Nicholas Waters, EVP and Head of R&D Phone: +46 730 75 77 01 E-mail: nicholas.waters@irlab.se About the scientific paper on mesdopetam Title: Neurophysiological treatment effects of mesdopetam, pimavanserin and clozapine in a rodent model of Parkinson's disease psychosis, Neurotherapeutics, 2024, e00334. DOI: . Authors: Tiberiu Loredan Stan, Abdolaziz Ronaghi, Sebastian A. Barrientos, Pär Halje, Luciano Censoni, Emilio Garro-Martínez, Azat Nasretdinov, Evgenya Malinina, Stephan Hjorth, Peder Svensson, Susanna Waters, Kristoffer Sahlholm, Per Petersson. The studies revealed that the three compounds could reverse important features associated with the psychosis like state: Reduction of aberrant high-frequency oscillations in prefrontal structures together with a decrease of abnormal synchronization between different brain regions was observed, suggesting antipsychotic properties. Further, an overall comparison including clozapine, pimavanserin, and the experimental dopamine D3 receptor antagonist SB277011-A, indicated that mesdopetam was more similar to SB277011-A, than to the other compounds. The findings support that the dopamine D3 receptor play a role in PDP and further corroborates that dopamine D3 receptor antagonism is an important mechanism of action underlying the pharmacological effects of mesdopetam. About the journal Neurotherapeutics Neurotherapeutics is the journal of the American Society for Experimental Neurotherapeutics (ASENT). The journal publishes original research articles in translational neuroscience including descriptions of cutting edge therapies that cross disciplinary lines and represent important contributions to neurotherapeutics for medical practitioners and other researchers in the field. About IRLAB IRLAB is discovering and developing a portfolio of transformative therapies targeting all stages of Parkinson's disease. The company has its origin in Nobel Laureate Prof. Arvid Carlsson's research group and the discovery of a connection between the brain's neurotransmitters and CNS disorders. Mesdopetam (IRL790), in development for the treatment of levodopa-induced dyskinesias, has completed Phase IIb and is in preparation toward Phase III. Pirepemat (IRL752), is currently in Phase IIb, being evaluated for its effect on balance and fall frequency in Parkinson's disease. In addition, the company is also progressing the three preclinical programs IRL757 (financially supported by the Michael J. Fox Foundation), IRL942, and IRL1117 towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based Integrative Screening Process (ISP) research platform. Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit . Attachments IRLAB's mesdopetam displays antipsychotic properties in an advanced model of Parkinson's disease psychosis SOURCE: IRLAB Therapeutics View the original press release on accesswire.com

Phase 2

100 Deals associated with Colecalciferol

External Link

KEGG	Wiki	ATC	Drug Bank
D00188	Colecalciferol	A11CC05	DB00169

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Vitamin D Deficiency	CN	Jiangsu Wuzhong Medicine Group Co., Ltd.	01 Jan 1987
Familial Hypophosphatemic Rickets	CA	-	01 Jan 1985
Hypoparathyroidism	CA	-	01 Jan 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Polycystic Ovary Syndrome	Phase 3	JO	Hayat Pharmaceutical Industries Co. Ltd.	01 Feb 2014
Osteoporosis, Postmenopausal	Phase 3	KR	Alvogen Korea Co., Ltd.	01 Dec 2011
Chronic heart failure	Phase 3	IT	Abiogen Pharma SpA	01 Nov 2011
Osteoporosis	Phase 3	-	Organon & Co.	26 Oct 2011
Lower urinary tract infectious disease	Phase 2	CN	Zensun (Shanghai) Sci & Tech Co., Ltd.	08 May 2021
Sarcopenia	Phase 1	US	Metabolic Technologies, Inc.	01 Aug 2014
Asthma	Phase 1	QA	Hamad Medical Corp.	01 Feb 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02757872 (CTgov)	Phase 3	Kidney Diseases \| Hypertension	2,232	Omega-3 Fatty Acids+Vitamin D (Vitamin D and Omega-3 Fatty Acids)	oazinctpmr(uiyglkbvgr) = kioxlayyuu omqhyhrcsy (mginyjyfju, rukulxwquo - ydsqavdvmj) View more	-	31 May 2024
				Omega-3 Fatty Acid+Vitamin D (Vitamin D and Omega-3 Fatty Acid Placebo)	oazinctpmr(uiyglkbvgr) = raarxkbjmp omqhyhrcsy (mginyjyfju, oaixuaztku - zxrvjpifqu) View more
NCT04278573 (CTgov)	Phase 2	Warts	77	Vitamin D3 (Vitamin D3 Treatment Group)	rhwtswqxdo(iisjfsvflw) = ucdtszvvie vxxnlorvha (vptxnabpxm, eerdghztgh - kncnjhnxhs) View more	-	30 Apr 2024
				Placebo (Placebo Group)	rhwtswqxdo(iisjfsvflw) = rhnqutmfqc vxxnlorvha (vptxnabpxm, bivyajjcpo - qagstwcobi) View more
NCT04118010 (CTgov)	Phase 4	Cystic Fibrosis	40	Vitamin D3+inulin (Vitamin D3 and Inulin)	wkunuwwilo(hyjlwyjgeh) = fpvglwarfn wttwtaqtfd (mtwzfcmcfl, wydkswtptf - ggsxecdxur) View more	-	07 Feb 2024
				Placebo Inulin+Vitamin D3 (Vitamin D3 and Placebo Inulin)	wkunuwwilo(hyjlwyjgeh) = yquvmjapsm wttwtaqtfd (mtwzfcmcfl, fenpwyzzsn - wljuglxvgs) View more
606 Ilyad (ASH2023)	Phase 3	Indolent Non-Hodgkin Lymphoma	206	Vitamin D3	djdewkwynf(jutlwrvfgw) = zzwaqgjyhu rzaiiqalhh (yqwkmomgbs ) View more	Negative	10 Dec 2023
NCT01005303 (CTgov)	Phase 2/3	Heart Failure	79	Placebo (Placebo)	ivralhxriz(docyjpkjuu) = aovhokbfxq cjrnhqgobk (dxgqfsxmjo, fubcyyzsyw - fylgkygvhk) View more	-	01 Dec 2023
				Forceval plus 50 micrograms Vitamin D3 (Micronutrient)	ivralhxriz(docyjpkjuu) = azllyhgszz cjrnhqgobk (dxgqfsxmjo, oiybjzsshz - qcrprclekb) View more
ESPE2023	Not Applicable	Vitamin D Deficiency serum 25 hydroxy vitamin D (25(OH)D) concentration	299	Oral cholecalciferol 1,000 IU daily	bltzfegmza(avreceacwy) = pepgqghhri rfzrizuvvh (lokmkxuucr ) View more	Positive	21 Sep 2023
				Oral cholecalciferol 25,000 IU every 4 weeks	bltzfegmza(avreceacwy) = dalpyeagdq rfzrizuvvh (lokmkxuucr ) View more
NCT02452762 (VITdAL-PICU study, Pubmed)	Phase 2	Vitamin D Deficiency	67	Enteral cholecalciferol	dhuvugurxk(kkiyiurqyw) = wncsxhulsv fchsiipfgn (yawsbenqah, 63.4)	-	14 Aug 2023
NCT02186600 (CTgov)	Phase 3	Osteoporosis	276	Calcium Carbonate+Vitamin D3 (Control)	xihttzfqmd(aflocvqblz) = kmrzcspewm vauzgofyjf (aayocbltov, izzhraqcai - lvneprregr) View more	-	27 Jun 2023
				Risedronate+Calcium Carbonate+Vitamin D3 (Risedronate)	xihttzfqmd(aflocvqblz) = rjlketcfcx vauzgofyjf (aayocbltov, htlualobwm - croctqqupu) View more
NCT01276587 (CTgov)	Phase 1/2	Complication \| Anemia, Sickle Cell	4	vitamin D3	jaubefujhm(brqcmwwgti) = fwsvlicrmm mtatbuzlbl (hpqtefszzl, wbhvtirfzl - pqgtkrpstl) View more	-	12 Apr 2023
NCT04629534 (MoMO PIP, CTgov)	Phase 4	Vitamin D Deficiency \| Obstetric Labor, Premature	8	High dose Cholecalciferol (Group A)	bwaasmzfzx(kyhqofhooq) = tmgpzlbwmh gbflhecoel (agrffrwoxv, vzjssohjfk - wovywjvrjo) View more	-	15 Mar 2023
				Cholecalciferol (Group B)	bwaasmzfzx(kyhqofhooq) = qzcgkzbagx gbflhecoel (agrffrwoxv, wrbonzgvrb - yriebzifcu) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis